Brief Report: PDF OnlyBlin O.; Azulay, J. P.; Desnuelle, C.; Billé-Turc, F.; Braguer, D.; Besse, D.; Branger, E.; Crevat, A.; Serratrice, G.; Pouget, J. Y.Clinical Neuropharmacology: April 1996 - p 189-192 Buy Abstract Summary: In a one-year parallel group double-blind placebo-controlled study of dextromethorphan (1.5 mg/kg) in amyotrophic lateral sclerosis, no significant differences were observed in the rate of progression (Norris scale) in comparing 24 patients randomly assigned to the dextromethorphan group and 25 patients randomly assigned to the placebo group. Of the 24 patients in the dextromethorphan group, 17 had limb onset and 7 had bulbar onset disease; average duration of disease was 12.5 ± 6 months and sex ratio (M:F) was 1.4:1. Of the 25 patients in the placebo group, 18 had limb onset and 7 had bulbar onset disease; average duration of disease was 9.9 ± 6 months and sex ratio (M:F) was 1.55:1. Dextromethorphan is a weak noncompetitive N-methyl-D-aspartate (NMDA) antagonist and higher doses or other potent NMDA receptor antagonists should be tested. Address correspondence and reprint requests to Dr. O. Blin at Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques, Hôpital de la Timone, F-13385 Marseille Cedex 5, France. © Williams & Wilkins 1996. All Rights Reserved.